Editorial Guidelines

SemaLiving publishes patient-facing GLP-1 informational and awareness content. Our editorial process is designed to make content practical, cautious, source-aware, and clear about its limits.

Our editorial promise

We write for patients and caregivers, not for vanity weight-loss seekers or self-directed medication use. Our goal is to help readers understand GLP-1 topics well enough to ask better questions of licensed clinicians.

Medical review status

SemaLiving is not a medically reviewed publication. Content is editorially reviewed for clarity, source quality, and consistency with our informational standard. It is not reviewed as individualized medical advice and should not be used to diagnose, prescribe, dose, or treat any condition.

How we choose topics

We prioritize questions patients ask after being prescribed or while discussing GLP-1 medications with a clinician: side effects, dosing transitions, nutrition, medication-source questions, condition-specific risks, and provider-comparison decisions.

How content is researched

• We start with authoritative sources where possible: FDA labels, prescribing information, manufacturer safety pages, PubMed-indexed research, CDC/NIH resources, clinical guidelines, and current provider terms.
• We verify medication-source, pricing, eligibility, and provider claims close to publication whenever a page compares telehealth providers or affiliate options.
• We avoid unsupported claims, “miracle” language, and generic wellness framing.
• We distinguish what research suggests from what it does not prove.

How content is written

• Use plain English and avoid unnecessary medical jargon.
• Frame readers as patients, caregivers, or people preparing for a clinician conversation.
• Do not tell readers to start, stop, switch, or change medication doses.
• Use “what may be common” and “when to call your doctor” framing for side effects.
• Disclose affiliate relationships where applicable.

How content is reviewed and updated

Each article should display a published date, last updated date, editorial review status, source standard, and clear notice that the page is not medically reviewed.

• Pages are updated when FDA labels, medication availability, provider terms, pricing, safety warnings, or clinical guidance materially changes.
• Provider and telehealth comparison pages require live rechecks before strong recommendation or pricing claims.
• Condition-specific and side-effect pages require careful sourcing and conservative language because they are YMYL-adjacent topics.

Minimum source standards by article type

Article type	Minimum source standard
Medication explainers	FDA label or Drugs@FDA record, manufacturer prescribing/safety information, and PubMed or guideline context where relevant.
Side-effect guides	FDA label warnings/adverse reactions, manufacturer safety information, and clear “when to call your doctor” escalation language.
Condition-specific guides	Clinical guideline or specialty-society source where available, PubMed literature, FDA label context, and explicit medical-advice limitations.
Nutrition and meal-planning pages	Medication safety context and condition-specific cautions for diabetes, kidney disease, pregnancy, eating-disorder history, or other relevant risks.
Telehealth/provider reviews	Provider website terms, pricing, medication-source disclosures, pharmacy/prescriber information where available, affiliate status, and date of verification.

Affiliate and medical boundaries

SemaLiving may earn commissions from partner links. Affiliate monetization does not replace clinical oversight, medication-source verification, or reader safety.

Corrections

If you see a claim that appears outdated, unclear, or incorrect, contact us through the Contact page with the URL and specific detail.